How to explain the differences between renin angiotensin system modulators.
about
AT2 receptor activities and pathophysiological implicationsCardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Additive effects of cilnidipine, an L-/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima Fatty rats with type 2 diabetes mellitus.Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.Angiotensin-(1-7)-mediated signaling in cardiomyocytes.Novel method to assess arterial insufficiency in rodent hind limb.Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers.Angiotensin II type-2 receptor-specific effects on the cardiovascular system.Olmesartan is More Effective Than Other Angiotensin Receptor Antagonists in Reducing Proteinuria in Patients With Chronic Kidney Disease Other Than Diabetic Nephropathy.Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease.Comparison of endothelial function improvement estimated with reactive hyperemia index between ramipril and telmisartan in hypertensive patients.Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.Role of the renin-angiotensin system on abdominal aortic aneurysms.Endothelial cell regulation of pulmonary vascular tone, inflammation, and coagulation.Protein DJ-1 and its anti-oxidative stress function play an important role in renal cell mediated response to profibrotic agents.A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.Maternal High-Fat Diet Causes a Sex-Dependent Increase in AGTR2 Expression and Cardiac Dysfunction in Adult Male Rat Offspring.Conceptual basis and methodology of the SOPHIA study.Association of angiotensin II type I and type II receptor genes polymorphisms with the presence of premature coronary disease and metabolic syndrome.Reduction in skeletal muscle fibrosis of spontaneously hypertensive rats after laceration by microRNA targeting angiotensin II receptor.Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases.The angiotensin II receptor antagonist, losartan, enhances regulator of G protein signaling 2 mRNA expression in vascular smooth muscle cells of Wistar rats.Chemotherapy and radiation regimens to breast cancer treatment induce changes in mRNA levels of renin-angiotensin system related genes in cardiac tissue.Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis
P2860
Q26829592-C277F80E-5ABD-42E8-8FA4-11112322DE3AQ33403831-EDB80A10-72B1-4180-AFF4-D00FD764110DQ33800185-C1A13933-2AA7-4F75-B744-442AF334C059Q34005101-F99BDE2B-6D58-4AA3-BB4D-7EFBA2E2BE11Q35829928-E05FB184-D5E7-400B-B309-77FFFCF3D3A6Q36558124-14A057DA-8B11-4EE5-AFF6-299A42506BBFQ36565036-349DA508-4487-42F7-A299-C4514FB6FE67Q37339329-C6DF473D-68FE-4ECB-A5E5-FCE363E2CE45Q37390013-35E0B7B9-821F-46CB-B3EE-51253AD7F06BQ37622578-3A15FE00-5419-4BD9-BF83-B5E7EC9DCA9BQ37642900-6B041F47-2E3B-41C2-ABFE-23B5BC78A574Q37802083-1289E2F7-0DAA-4DB6-9762-1F6B093E22B7Q38153772-2ACB8800-0756-4086-9BE9-E796EF8BF010Q38423843-2B4AA6EE-F153-46BB-9E7A-7E073B9D91C6Q38775811-E1995065-AB17-4DB8-B4E4-515C65A64B5BQ40818988-DE5DE645-1CE8-4EA9-A630-9141FBF7D61BQ44356539-70F8FA37-6555-4D97-9550-DBD493B9B04EQ46885454-8D66B14C-B559-4AB6-84C2-30B7B464B6EDQ46950810-CE8F328C-A43C-45A6-9563-89416A74F140Q47119733-AF7C25B7-B752-4B56-BC52-5DC02DC3458EQ50075636-397712C7-7360-4FB3-9136-DA8B1D598355Q50892340-1C2AC45F-1CD1-4F62-B119-85A8D61BA96AQ51298069-B3F00BFA-64CA-44B7-9D3A-B465BF003A48Q57167538-93DE1E39-A6C9-481B-B271-D3115F0DF08C
P2860
How to explain the differences between renin angiotensin system modulators.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
How to explain the differences between renin angiotensin system modulators.
@ast
How to explain the differences between renin angiotensin system modulators.
@en
How to explain the differences between renin angiotensin system modulators.
@nl
type
label
How to explain the differences between renin angiotensin system modulators.
@ast
How to explain the differences between renin angiotensin system modulators.
@en
How to explain the differences between renin angiotensin system modulators.
@nl
prefLabel
How to explain the differences between renin angiotensin system modulators.
@ast
How to explain the differences between renin angiotensin system modulators.
@en
How to explain the differences between renin angiotensin system modulators.
@nl
P1476
How to explain the differences between renin angiotensin system modulators.
@en
P2093
Bernard I Levy
P304
P356
10.1016/J.AMJHYPER.2005.05.005
P433
P577
2005-09-01T00:00:00Z